California Stem Cell Agency Symposium: 'Vague Fears' vs. Potential Genetic Alteration of Human Race
By David Jensen,
California Stem Cell Report
| 06. 11. 2015
[Quotes CGS's Marcy Darnovsky]
Untitled Document
California’s $3 billion stem cell agency has called a high-level meeting for next fall to examine a "red-hot" issue that many prominent researchers say could lead ultimately to alteration of the human race.
The topic is a technique that makes it much easier to alter the genetic make-up of individuals in a way that can be inherited by their offspring.
In April, scientists in China reported genetically modifying human embryos in what was regarded as a “world first.” (See
here and
here.)
More recently
Marcy Darnovsky, executive director of the
Center for Genetics and Society in Berkeley,
wrote on May 28 about how the subject was viewed at a meeting called, “Biotech and the Ethical Imagination: A Global Summit.”
“The far end of techno-enthusiastic perspectives, both on human germline modification specifically and on biotech in general, was represented by Harvard experimental psychologist and popular science writer Steven Pinker. In...
Related Articles
Not the species, certainly, but the Institute of that name, which was founded by transhumanist philosopher Nick Bostrom in 2005 as a research group at Oxford University. According to a recently posted Final Report, its goal was “to pursue the big questions in a transdisciplinary way” by pulling together “researchers from disciplines such as philosophy, computer science, mathematics, and economics.” This evolved before long into the study and promotion of “effective altruism” and “longtermism” as...
By Yelena Biberman and Jonathan D. Moreno, Bioethics Forum | 04.16.2024
A quiet biological revolution in warfare is underway. The genome is emerging as a new domain of conflict. The level of destruction that only nuclear weapons could previously achieve is fast becoming as accessible as a cyberattack.
Now for the...
By Tristan Manalac, BioSpace | 04.02.2024
Verve Therapeutics has suspended enrollment in the Phase Ib Heart-1 study evaluating its lead gene editing program VERVE-101 following a serious adverse event, the company announced Tuesday.
A patient, who received a 0.45-mg/kg dose of VERVE-101, developed a grade 3...
By Timnit Gebru and Émile P. Torres, First Monday | 04.14.2024
The stated goal of many organizations in the field of artificial intelligence (AI) is to develop artificial general intelligence (AGI), an imagined system with more intelligence than anything we have ever seen. Without seriously questioning whether such a system can...